Reneo Pharmaceuticals Inc. (RPHM) Income Statement Analysis - Revenue, Earnings & Profitability Metrics - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Reneo Pharmaceuticals Inc...

    NASDAQ: RPHM · Real-Time Price · USD
    18.20
    16.47 (952.02%)
    At close: Oct 04, 2024, 10:00 PM

    Reneo Pharmaceuticals Income Statement

    Financials in USD. Fiscal year is January - December.

    undefined peaked at n/a in undefined and hit its lowest at n/a in undefined. Over the past five years, it has declined by undefined%.

    Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
    Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
    Revenue
    		 n/a n/a n/a n/a
    Cost of Revenue
    		 n/a n/a 529K 50K
    Gross Profit
    		 n/a -525K -529K -50K
    Operating Income
    		 -54.39M -83.05M -53.85M -39.82M
    Interest Income
    		 2.01M n/a 1.89K 48.00
    Pretax Income
    		 n/a -77.39M -51.95M -39.77M
    Net Income
    		 n/a -77.39M -50.06M -39.77M
    Selling & General & Admin
    		 10.59M 25.79M 16.14M 11.65M
    Research & Development
    		 43.8M 56.09M 37.7M 28.17M
    Other Expenses
    		 n/a 650K n/a 48K
    Operating Expenses
    		 54.39M 83.05M 53.85M 39.82M
    Interest Expense
    		 -300K n/a n/a n/a
    Selling & Marketing Expenses
    		 n/a n/a n/a n/a
    Cost & Expenses
    		 n/a 83.05M 53.85M 39.82M
    Income Tax Expense
    		 n/a n/a -1.89M -186.56K
    Shares Outstanding (Basic)
    		 34.47M 33.61M 24.5M 18.14M
    Shares Outstanding (Diluted)
    		 34.47M 33.61M 24.5M 18.14M
    EPS (Basic)
    		 n/a -2.3 -2.04 -2.19
    EPS (Diluted)
    		 n/a -2.3 -2.04 -2.19
    EBITDA
    		 -54.39M -82.23M -53.76M -39.77M
    EBIT
    		 n/a -82.4M -53.83M -39.82M
    Depreciation & Amortization
    		 n/a 170K 529K 50K

    Add to Watchlist